title: Hepatitis C virus-induced leuko-thrombocytopenia and haemolysis.
abstract: Hepatitis C virus (HCV) has been recognized as the cause of thrombocytopenia occurring in patients with chronic hepatitis C, possibly through autoimmune mechanisms. A patient is described with B cell chronic lymphocytic leukaemia, presenting with a marked leuko-thrombocytopenia and an associated mild haemolysis secondary to HCV infection, in the absence of clinical and biochemical signs of hepatitis. Anti-HCV antibodies were detected in the serum both by ELISA and RIBA but not 2 months before the onset of cytopenia. The presence of HCV RNA was documented both in the peripheral blood mononuclear cells and in the bone marrow by reverse transcriptase polymerase chain reaction of the 5' untranslated region of the viral genome. Of interest, HCV RNA was also found in the serum, showing that viraemia was associated with the presence of circulating anti-HCV antibodies. HCV genotyping, performed by PCR amplification of the core region, revealed the presence of an unclassifiable genotype. The hypothetical mechanisms leading to HCV-induced cytopenia in this patient are briefly discussed. Treatment with corticosteroids was effective in controlling blood cell counts, without increasing viraemia and deterioration of liver disease. HCV infection should be considered in the differential diagnosis of possible causes of cytopenia, mainly in immunosuppressed patients, even in absence of clinical and biochemical signs of hepatitis.
authors.affiliation: Department of Medical Sciences, University of Modena, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Emilia
authors.forename: M
authors.initials: M
authors.lastname: Luppi
authors.forename: M G
authors.initials: MG
authors.lastname: Ferrari
authors.forename: P
authors.initials: P
authors.lastname: Barozzi
authors.forename: R
authors.initials: R
authors.lastname: Marasca
authors.forename: G
authors.initials: G
authors.lastname: Torelli
mesh_terms: D000368:Aged; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D005838:Genotype; D006461:Hemolysis; D016174:Hepacivirus / Q000235:genetics / Q000302:isolation & purification; D006526:Hepatitis C / Q000150:complications*; D018937:Hepatitis C Antibodies / Q000097:blood; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy / Q000821:virology*; D007970:Leukopenia / Q000188:drug therapy / Q000821:virology*; D008297:Male; D011241:Prednisone / Q000627:therapeutic use; D012367:RNA, Viral / Q000097:blood; D013921:Thrombocytopenia / Q000188:drug therapy / Q000821:virology*; D014750:Vincristine / Q000627:therapeutic use; D014766:Viremia / Q000821:virology
chemical_list: D000893:Anti-Inflammatory Agents; D018906:Antineoplastic Agents, Alkylating; D000972:Antineoplastic Agents, Phytogenic; D018937:Hepatitis C Antibodies; D012367:RNA, Viral; D014750:Vincristine; D003520:Cyclophosphamide; D011241:Prednisone